BiotechTube

safusidenib + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioma

Conditions

Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, IDH-Mutant, Grade 2, Oligodendroglioma, Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted

Trial Timeline

Jun 5, 2023 → Dec 1, 2030

NCT ID
NCT05303519

About safusidenib + Placebo

safusidenib + Placebo is a phase 3 stage product being developed by Nuvation Bio for Glioma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05303519. Target conditions include Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05303519Phase 3Recruiting

Competing Products

20 competing products in Glioma

See all competitors
ProductCompanyStageHype Score
TemozolomideNovocurePhase 1
28
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
33
LY2157299 + LomustineEli LillyPhase 1
33
DS-1001bDaiichi SankyoPhase 2
52
DS-1001bDaiichi SankyoPhase 1
33
Perampanel + Standard of CareEisaiPhase 1/2
41
Temozolomide and BevacizumabEisaiPhase 2
52
TemozolomideEisaiPhase 2
52
Gliadel Wafer + TemozolomideEisaiPhase 2
52
Palonosetron (PALO)EisaiPhase 2
52
Gliadel/Avastin/CPT-11EisaiPhase 2
52
Lenvatinib + BevacizumabEisaiPhase 2
52
Granisetron + OndansetronKyowa KirinPhase 2
52
Binimetinib 15 MGOno PharmaceuticalPhase 2
52
EnzastaurinEli LillyPhase 2
52
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
33
LY2157299 + Radiation + TemozolomideEli LillyPhase 1/2
41
Abemaciclib + TemozolomideEli LillyPhase 2
52
DSP-0390Sumitomo PharmaPhase 1
33
DSP-0390Sumitomo PharmaPhase 1
33

Other Products from Nuvation Bio

Taletrectinib + PlaceboPhase 3
72
Taletrectinib + CrizotinibPhase 3
72
AB-106Phase 2
47
AB-106Phase 2
47
TaletrectinibPhase 2
47